O10.04 THE RANDOMIZED, MULTICENTER GLARIUS TRIAL INVESTIGATING BEVACIZUMAB/IRINOTECAN VS STANDARD TEMOZOLOMIDE IN NEWLY DIAGNOSED, MGMT-NON-METHYLATED GLIOBLASTOMA PATIENTS: FINAL SURVIVAL RESULTS AND QUALITY OF LIFE

BACKGROUND: There is a need for more effective therapies in newly diagnosed glioblastoma (GBM) patients with an MGMT-non-methylated tumor. The GLARIUS trial explored the efficacy of bevacizumab (BEV) + Irinotecan (IRI) as compared to standard TMZ in the first-line therapy of MGMT-non-methylated GBM....

詳細記述

保存先:
書誌詳細
主要な著者: Herrlinger, U., Schäfer, N., Steinbach, J.P., Weyerbrock, A., Hau, P., Goldbrunner, R., Leutgeb, B., Urbach, H., Stummer, W., Glas, M.
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2014
主題:
Oral Presentations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4185856/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou174.85
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料